GSK to supply cervical cancer vaccine to support GAVI project
Under the commitment, GSK will supply doses of Cervarix (Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed)) to four new GAVI demonstration projects at reasonably discounted rate.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.